Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT 2 receptor agonist with favorable pharmacokinetic properties TORONTO / Apr 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to... Read More

Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending applications Company expects to commence enrollment for a multinational, multisite Phase 3 program evaluating CYB003 in Major Depressive Disorder... Read More

TORONTO / Apr 10, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare... Read More

TORONTO / Mar 19, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce the closing of the Company’s previously announced private placement (the “ Private Placement ”) of... Read More

TORONTO / Mar 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief... Read More

Anxiety disorders are the most prevalent mental health disorders globally 1 , contributing to over 28 million disability-adjusted life years (“DALYs”) 2 Highly scalable intermittent treatment for Generalized Anxiety Disorder (“GAD”) with an expected treatment time of approximately 90-minutes from a single administration Proprietary deuterated dimethyltryptamine (“DMT”) molecule with U.S. composition of matter patent granted... Read More

With U.S. Food and Drug Administration (“FDA”) alignment on multisite, multinational Phase 3 program design Company expects to commence Phase 3 program around mid-year 2024 15 U.S. clinical trials sites targeted; European sites to be added Robust and sustained improvement in depression symptoms with CYB003 at four months with 75% of patients in remission from depression after two doses (16mg) Breakthrough Therapy Designation... Read More

TORONTO / Mar 13, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement (the “ Private Placement ”) of 348,837,210 common shares in the capital of the... Read More

Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines First known BTD granted by the FDA for an adjunctive psychedelic based therapy... Read More

Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer TORONTO / Mar 12, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to... Read More

TORONTO / Feb 27, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the TD Cowen 44 th Annual Health Care... Read More

Reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”), demonstrating a 79% remission rate from depression Announced positive topline results from Phase 1 studies of proprietary deuterated dimethyltryptamine (“dDMT”) molecules CYB004 and SPL028, supporting clinical advancement and the successful... Read More

Newly issued patents include protection for injectable formulations and synthesis methods for the preparation of dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”) Patent protection further strengthens intellectual property portfolio in the 3 rd largest pharmaceutical market globally Cybin’s patent portfolio now includes 51 granted patents and over 170 pending applications TORONTO / Feb 07, 2024 / Business Wire / Cybin... Read More

Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT U.S. composition of matter patent granted with protection expected through 2041 Company to initiate a randomized, double-blind, active controlled Phase 2a study in Q1 2024 TORONTO / Jan 23,... Read More

Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment Intramuscular (“IM”) dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants Both IV and IM routes were safe and well-tolerated, with potential for IM administration to provide more convenient,... Read More

Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two doses of CYB003 (12mg) Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications Multinational operations support scaling to Phase 3 trial of CYB003 in MDD and Phase 2 study of deuterated dimethyltryptamine (“dDMT”) in... Read More

Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications Recently announced positive topline data from Phase 2 study of CYB003 in major depressive disorder showed 79% of... Read More

Poster presentations highlight data across Cybin’s CYB003 and deuterated DMT clinical programs, as well as preclinical development programs TORONTO / Dec 05, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment... Read More

Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from... Read More

Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark Topics include topline Phase 2... Read More

Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder TORONTO / Nov 16, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next generation... Read More

TORONTO / Nov 15, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience (“SFN”) taking place November 11-15,... Read More

Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutional shareholders Strengthened patent portfolio with the addition of four new patents Completed acquisition of Small Pharma Inc. Topline clinical readout of Phase 2 efficacy data for... Read More

TORONTO / Nov 14, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously announced underwritten offering (the “ Offering ”). In connection with the Offering,... Read More

TORONTO / Nov 10, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten offering (the “ Offering ”) of 66,666,667 units of the Company (the “ Units ”) to one of... Read More

CEO Doug Drysdale to speak on panel about innovations in mental health care on November 7, 2023 TORONTO / Nov 03, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

TORONTO / Nov 01, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today provided an update on its clinical-stage programs and key upcoming milestones across its development pipeline. “The clinical... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated DMT programs New European patent further strengthens intellectual property portfolio, which now includes 33 granted patents and over 170 pending applications TORONTO / Oct 26, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a... Read More

New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis Intellectual Property portfolio provides robust protection for most extensive deuterated DMT portfolio in the sector Cybin’s Intellectual Property portfolio now consists of 32 granted patents and over 170 pending applications TORONTO / Oct 25, 2023 / Business Wire / Cybin Inc. (NYSE... Read More

Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy TORONTO & LONDON / Oct 23,... Read More

LONDON & TORONTO / Oct 17, 2023 / Business Wire / Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based... Read More

TORONTO / Oct 12, 2023 / Business Wire / Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on October... Read More

Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT 2A receptor full agonist with therapeutic potential” Highlights preclinical work done to support selection of a development candidate for the Company’s phenethylamine program Cybin to moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit titled “Making Psychedelic Clinical Trials a Reality: Mitigating... Read More

TORONTO / Oct 04, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Inaugural Biotech CNS/Neuro Summit, taking... Read More

Topline efficacy data expected in Q4 2023 Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 TORONTO / Oct 03, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today... Read More

TORONTO / Sep 26, 2023 / Business Wire / Cybin Inc . (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling... Read More

TORONTO / Sep 25, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will... Read More

TORONTO / Sep 21, 2023 / Business Wire / Cybin Inc . (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The... Read More

Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval Previously announced acquisition of Small Pharma Inc. expected to close in Q4 2023, creating an international clinical-stage leader in novel psychedelic therapeutics... Read More

Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio in the psychedelic drug development sector with 29 patents granted and over 150 patents pending TORONTO / Sep 05, 2023 / Business Wire / Cybin Inc.... Read More

All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy Combined portfolio creates the industry’s largest, most advanced, well-protected deuterated DMT program Combination creates the largest intellectual property portfolio in the psychedelic drug... Read More

TORONTO / Aug 23, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the “ ATM Program ”) that allows Cybin to issue and sell up... Read More

CYB003 capsule formulation is designed to be stable, dose flexible, patient-friendly and commercially scalable Shipments of CYB003 capsules to clinical sites expected in Q1 2024 Recently granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 TORONTO / Aug 17, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “... Read More

Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 Company’s intellectual property portfolio now encompasses 2 granted U.S. patents, and over 50 pending patent applications across 6 patent families TORONTO / Aug 15, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage... Read More

Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023 Preparations underway for pivotal studies, including the development of a scalable psychedelic facilitation training program, EMBARK CT , and partnership with Worldwide... Read More

TORONTO / Aug 04, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has closed its previously announced overnight marketed public offering (the “ Offering ”). In connection with the... Read More

To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg Phase 2 topline efficacy data expected in Q3/Q4 2023 TORONTO / Aug 02, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative... Read More

TORONTO / Aug 01, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight marketed public offering (the “ Offering ”) of an aggregate of 24,264,706 units of the... Read More

TORONTO / Jul 31, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed public offering of units of the Company (the “Units”) at a price per Unit and for... Read More

TORONTO / Jul 27, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual... Read More

Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder in Q3/Q4 2023 TORONTO / Jul 26, 2023 / Business Wire / Cybin Inc . (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage... Read More

Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly Phase 2 efficacy data for CYB003 in major depressive disorder expected in Q3/Q4 2023 U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for pivotal studies expected following topline efficacy data readout TORONTO / Jul 24, 2023 / Business Wire / Cybin Inc. (NYSE... Read More

TORONTO / Jul 20, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their publication titled " Measuring acute effects of subanesthetic ketamine on... Read More

LOS ANGELES / Jul 20, 2023 / Business Wire / Kernel, a leader in non-invasive neuroimaging, announces the publication of their study " Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS ," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), underscores the ability of Kernel’s Flow1... Read More

EMBARK for Clinical Trials (“EMBARK CT ”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies American Medical Association (“AMA”)’s new CPT codes will support potential reimbursement of in-person monitoring and support provided during psychedelic treatment TORONTO / Jul 12, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”),... Read More

Cybin’s Chief Medical Officer Amir Inamdar to participate in a fireside chat on July 6, 2023 TORONTO / Jun 30, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Amir Inamdar, MBBS, DNB... Read More

TORONTO / Jun 21, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, and Allison House-Gecewicz, Cybin’s SVP of Clinical Operations, will be... Read More

TORONTO / Jun 15, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual... Read More

C$70M in potential funding through a combination of the previously announced common share purchase agreement and current “at-the-market” equity program helps support upcoming clinical milestones Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 TORONTO / Jun 08, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “... Read More

Michael Palfreyman Ph.D. and Brett Greene, who joined Cybin as part of the acquisition of Adelia Therapeutics, move into advisory roles Alex Nivorozhkin Ph.D. continues as Chief Scientific Officer TORONTO / Jun 05, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and... Read More

TORONTO / Jun 01, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York... Read More

- Share purchase agreement further strengthens Company’s position to deliver on value-driving clinical milestones - TORONTO / May 30, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has... Read More

CYB004, a deuterated dimethyltryptamine (“dDMT”) molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 Parts A and B of Phase 1 study complete; Part C to determine safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) of escalating doses of CYB004 in healthy volunteers Phase 1 topline safety and efficacy data expected in Q3 2023 TORONTO / May 24,... Read More

Advancing to first-in-human dosing of CYB004, a proprietary deuterated DMT molecule CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT Phase 1 topline data expected in Q3 2023 TORONTO / May 09, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing... Read More

CEO Doug Drysdale to speak on a mental health panel on May 2, 2023 TORONTO / Apr 28, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking... Read More

TORONTO / Apr 12, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access (“EMBARK OA”), a free online foundational training course for psychedelic facilitation. EMBARK OA is... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023. Mr. Drysdale’s fireside chat will be webcast live on Tuesday, March... Read More

Cybin CEO, Doug Drysdale and Wellness Icon Deepak Chopra to be featured on panel titled Open Minds: Innovations in Consciousness, Psychedelics & Mental Health - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit organization dedicated to improving health and well-being founded... Read More

CYB003 Phase 1/2a interim data demonstrate rapid and short-acting effects; robust psychedelic effects at low doses; positive safety and tolerability profile; top-line efficacy data expected late Q3 2023 Initial findings from Phase 1 CYB004-E study suggest IV DMT was well-tolerated; study design expanded to accelerate first-in-human dosing of CYB004 Company to host R&D Day webcast today, February 28, 2023, at 10:00am ET Cybin... Read More

Company streamlining to fully focus on achieving near-term, mid-term and long-term clinical milestones This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf prospectus dated July 5, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to... Read More

Company to provide CYB003 Phase 1/2a interim study readout and update on its CYB004 program at upcoming R&D Day on February 28, 2023 This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf prospectus dated July 5, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company... Read More

Marks first ever trial to evaluate deuterated DMT in humans Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods CYB004 is a patented proprietary molecule protected through 2041 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “... Read More

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced that it will host a virtual R&D Day on Tuesday, February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET. The event, which will be hosted by Cybin’s leadership team, will provide a progress update on the Company’s development pipeline of differentiated... Read More

Study supports earlier findings and demonstrates that Kernel Flow provides a functional measure of blood oxygenation changes in the brain associated with neural activity Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba... Read More

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics ® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004. "Based on preclinical data, CYB004 has shown... Read More

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today outlined its upcoming priorities and near-term milestones that support the development of its CYB003 and CYB004 clinical programs aimed at addressing multiple mental health conditions. “Cybin enters 2023 with the potential to reach a number of value-driving milestones,... Read More

Strategic initiatives and pipeline advancements support clinical development of CYB003 and CYB004 exploring potential therapeutic benefits using psychedelic-based molecules Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to provide a year-end summary of its key milestone accomplishments in 2022. "2022 was a... Read More

New findings underscore potential of CYB003 as a novel psychedelic-based therapeutic for the treatment of depression Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology... Read More

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA. “It is exciting to be part... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“ DMT ”) has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce its participation in the following upcoming investor events: Jefferies London Healthcare Conference, November 15-17, 2022 Doug Drysdale, Cybin’s Chief Executive Officer, will present on November 15, 2022 at 8:00 a.m. GMT and host investor... Read More

Cybin’s Director of Neuropharmacology, Amy Reichelt Ph.D. to present a talk titled “CYB004-Modifications to DMT to Enhance its Therapeutic Potential” Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced an upcoming presentation at the Neuropsychiatric & Psychedelics Drug Development Summit taking place October... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics ® ”, today announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy co-developed by Alex Belser, Ph.D., and Bill Brennan, Ph.D. The... Read More

Cybin and The Chopra Foundation continue to work together to advance the research and education of psychedelic-based therapeutics as a new paradigm for the treatment of mental health Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , and The Chopra Foundation (“Foundation”), a not-for-profit organization dedicated to... Read More

Cybin strengthens its intellectual property library with more than 20 active patent filings across six patent families, and multiple license agreements that provide access to over 35 patents and applications Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to provide an update on its intellectual property... Read More

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“ Mindset ”) to acquire an exclusive license to an extensive targeted class of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics TM , is pleased to announce its participation in the following upcoming conferences: Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event, September 21, 2022 in Haarlem, Amsterdam Doug Drysdale, Cybin’s Chief Executive Officer,... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, announced that it has successfully achieved its research and development milestones that helped to build and progress its innovative pipeline of investigational psychedelic therapeutics ahead of projected timelines. These milestones were set forth in the acquisition... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “ Transaction Agreement ”)... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”). “To commence dosing in our first-in-human Phase 1/2a trial is a tremendous milestone for Cybin,... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 24 th Annual Global Investment Conference taking place on September 12-14, 2022. Mr. Drysdale’s fireside chat will be... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 15, 2022 (the “ Meeting ”). There were 71 shareholders represented in person or by proxy at the Meeting holding 47,019,721... Read More

Cybin Announces Up To USD$35 Million At-the-market Equity Program Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, announced today that it has established an at-the-market equity program (the “ ATM Program ”) that allows Cybin to issue and sell up to USD$35,000,000 of common shares (“ Shares ”) in the capital of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights. “Looking back at the last 12 months, we have made positive progress toward our goal of advancing psychedelics to therapeutics. In that time, we have... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42 nd Annual Growth Conference being held at the InterContinental Boston Hotel on August 8-11, 2022. Mr. Drysdale’s fireside chat... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” announced today that its 2022 Annual Meeting of Shareholders will be held virtually on Monday, August 15, 2022 at 10:00 a.m. ET. The notice of annual meeting and proxy statement containing meeting details are expected to be available on or about July 25, 2022 to... Read More

Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). CYB003 is being developed by Cybin Inc.... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine (“ DMT ”) study (the “... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Y2, Q3 (i) as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “ Transaction Agreement ”)... Read More

Cybin Inc . (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it has received a “may proceed letter” and Investigational New Drug Application (“IND”) clearance from the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003. CYB003 is a proprietary deuterated... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights. The Company also reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 1st Annual Mental Health Conference being held at the Lotte New York Palace Hotel on June 27, 2022. Mr. Drysdale’s fireside chat... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the “ Company” ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that it has received Institutional Review Board (“IRB”) approval to begin the first-in-human Phase 1/2a clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “IRB approval... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”) to... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii), (iii) as contemplated by the terms of a contribution... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK Psychedelic Facilitator Training Program. Recognizing the crucial importance of supporting psychedelic study facilitators with quality training, Cybin has brought together... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, is pleased to announce the publication of a peer-reviewed article introducing EMBARK , a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. “It’s a... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™,” today announced that it will host a virtual Key Opinion Leader webinar on Thursday June 9, 2022, from 11:00 a.m. ET to 12:00 p.m. ET. The webinar will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange (“NYSE”) in New York City. Cybin, whose shares commenced trading on the NYSE American on August 5, 2021, was the first psychedelics company... Read More

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference being held at the Fontainebleau Miami Beach May 23-26, 2022. Mr. Drysdale’s fireside chat will... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicines taking place May 27-29,... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the KCSA Psychedelics Virtual Investor Conference at 11:00 a.m. ET on Thursday, April 28, 2022. This will be a live, interactive online event where investors are invited to ask... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004, delivered via inhalation. Specifically, inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (PCT) patent application... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics ™ ” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat and panel discussion at the Benzinga Psychedelics Capital Conference being held at the Fontainebleau Miami Beach on Tuesday, April 19, 2022. Mr. Drysdale’s... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics ™ ”, is pleased to report the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (MDD). Data from in vivo preclinical studies demonstrate that CYB003 is well-tolerated following... Read More

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing “Psychedelics to Therapeutics™”, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Year 1 Q4 (vi); Year 2 Q2 (ii); Year 2 Q2 (v) and Year 2, Q3 (iii) as contemplated by the terms of a contribution agreement... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study is evaluating the participants experience wearing Kernel Flow while in an altered state of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28 th - 30 th from 9:00 a.m. - 5:00 p.m. ET. Mr. Drysdale’s presentation... Read More

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Psychedelic Therapies Offer Hope for Mental Health,” please visit: https://nnw.fm/JeGwq Neural plasticity is... Read More

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange (“ NYSE American ”) on August 5, 2021, under the symbol “ CYBN ” . In addition to listing and trading on the NYSE American in U.S. dollars, Cybin’s common shares will continue to be... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange (“ NYSE American ”). The Company expects its common shares will open for trading on the NYSE American on or about August 5, 2021, under the symbol “CYBN” . Doug... Read More

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has launched an overnight marketed public offering of common shares in the capital of the Company (the “ Shares ”) at a price per Share and for aggregate gross proceeds to be determined in the context of the market (the “ Offering ”). The definitive... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “ NYSE American ”). Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy. The company is evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive improved patient... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be participating in a panel discussion at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13, 2021. The panel details are as follows: Panel: Emerging Psychedelic Therapies In The Field... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical research organizations, including the transfer of its intellectual property assets to its recently formed wholly-owned Ireland subsidiary. The Company continues its... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has entered into an exclusive research and development collaboration agreement (the “ Collaboration Agreement ”) with TMS NeuroHealth Centers Inc., a wholly-owned subsidiary of Greenbrook TMS Inc. (TSX:GTMS) (NASDAQ:GBNH) (“ Greenbrook ”). Greenbrook operates 129... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. Unless otherwise indicated, all amounts in this press release are in Canadian dollars. Recent Business Highlights: Received Institutional Review Board approval to initiate phase II clinical... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period commencing January 1, 2021, as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The details are as follows: Date: Monday, June 28, 2021 Time: 12:30 PM ET Webcast: https://www.youtube.com/watch?v=Red-_CXhLmY The... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the addition of Dr. Thomas Laughren, to the Clinical Advisory Board. Dr. Thomas Laughren formerly served as the Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA where he served for 29 years. As the former Director for... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Life Sciences Investor Forum on June 24, 2021. The presentation details are as follows: Date: Thursday, June 24, 2021 Time: 9:00 AM Eastern Time Link:... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51 st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. The Cybin Research and Development team has completed its 51 st in-vitro and in-vivo evaluation of... Read More

EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 10 th Emerging Growth Conference. For the first time, Emerging Growth teams with Investors Hub, one of the top investing websites and apps providing streaming market data tools and over 30,000 message boards focused on public... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Emerging Growth Conference on June 23, 2021. The presentation details are as follows: Date: Wednesday, June 23, 2021 Time: 2:00 PM Eastern Time Webcast:... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004. “People struggle with many different mental health challenges, but anxiety affects more people... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The presentation details are as follows: Date: Thursday, June 17, 2021 Time: On demand, beginning at 7:00 AM... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it will co-sponsor a randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the 2021 LD Micro Invitational XI. The presentation details are as follows: Date: Thursday, June 10, 2021 Time: 3:30pm Eastern Time Webcast: https://ldmicrojune2021.mysequire.com/ The presentation will be webcast live using the link... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics. On January 11, 2021 Cybin announced that it would be partnering with Kernel to leverage Kernel’s proprietary Kernel Flow... Read More

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Jefferies Virtual Healthcare Conference 2021. The presentation details are as follows: Date: Tuesday, June 1, 2021 Time: 1:00PM Eastern Time Webcast: https://wsw.com/webcast/jeff174/clxpf/2010555 The... Read More